
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc has demonstrated a strong potential for growth, particularly with the anticipated approval of PRGN-2012, which is positioned as the leading therapy for recurrent respiratory papillomatosis (RRP). The company has provided compelling data indicating that PRGN-2012 results in significant reductions in the need for surgical procedures, suggesting a favorable acceptance among specialists in the field. Additionally, the high likelihood of approval by the August 27, 2025 PDUFA date further enhances the optimism surrounding Precigen's future revenue streams and market presence.
Bears say
Precigen Inc faces significant challenges in maintaining or growing its reported sales due to adverse dynamics in the broader volume and pricing environment as well as intra-market competition. The company has a history of financial losses and has not demonstrated consistent profitability, heightening concerns about its long-term viability. Additionally, balance sheet risks further complicate its financial outlook, raising questions about its operational stability and capacity to compete effectively.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares